Contraception across transgender.
Journal
International journal of impotence research
ISSN: 1476-5489
Titre abrégé: Int J Impot Res
Pays: England
ID NLM: 9007383
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
02
07
2020
accepted:
21
01
2021
revised:
19
01
2021
pubmed:
10
2
2021
medline:
17
11
2021
entrez:
9
2
2021
Statut:
ppublish
Résumé
Sexual and reproductive issues are essential elements of well-being in cisgenders as well as for the transgender population. Gender-affirming hormonal treatments (GAHTs) aim to induce phenotypical changes congruent with the desired gender and subsequent reduction of gender dysphoria. While genital surgical procedures including hysterectomy and/or adenectomy cause permanent loss of ability to conceive, GAHT may induce a varying degree of reversible loss of fertility. For these reasons, transgender men and women need to be counseled concerning contraceptive options and potential effects of treatment on reproductive function before initiating GAHT. The literature reports that sexual activity with genital involvement is performed by less than half of transgender persons who have been sexually active with a partner in the past. Testosterone (T) is the most commonly used compound in transmen and usually leads to amenorrhea within 1-12 months from first administration, however cessation of menses does not mean anovulation. Some studies report cases of unintended pregnancies among transgender men under masculinizing therapy, therefore T treatment cannot be considered a contraceptive option. Currently available contraceptive options have pros and cons in transmen and scarce literature exists on their use. The effects of GAHT on fertility in transwomen are even less well known. Prolonged estrogen exposure induces sperm suppression and morphological changes of the spermatozoa, however the degree of resulting pregnancy protection is unclear. Further research to inform the contraceptive counseling in this population is mandatory.
Identifiants
pubmed: 33558672
doi: 10.1038/s41443-021-00412-z
pii: 10.1038/s41443-021-00412-z
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
710-719Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature.
Références
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-V). 5th ed. Arlington: American Psychiatric Publishing; 2013.
T’Sjoen G, Arcelus J, Gooren L, Klink DT, Tangpricha V. Endocrinology of transgender medicine. Endocr Rev. 2019;40:97–117.
pubmed: 30307546
Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102:3869–903.
pubmed: 28945902
Richards C, Seal L. Trans people’s reproductive options and outcomes. J Fam Plan Reprod Health Care. 2014;40:245–7.
Holmberg M, Arver S, Dhejne C. Supporting sexuality and improving sexual function in transgender persons. Nat Rev Urol. 2019;16:121–39.
pubmed: 30375495
Auer MK, Fuss J, Höhne N, Stalla GK, Sievers C. Transgender transitioning and change of self-reported sexual orientation. PLoS ONE. 2014;9:e110016.
pubmed: 25299675
pmcid: 4192544
Roberts AL, Rosario M, Corliss HL, Koenen KC, Austin SB. Childhood gender nonconformity: a risk indicator for childhood abuse and posttraumatic stress in youth. Pediatrics. 2012;129:410–7.
pubmed: 22351893
pmcid: 3289524
Becasen JS, Denard CL, Mullins MM, Higa DH, Sipe TA. Estimating the prevalence of HIV and sexual behaviors among the US transgender population: a systematic review and meta-analysis, 2006-2017. Am J Public Health. 2019;109:e1–8.
pubmed: 30496000
pmcid: 6301428
Jones RK, Witwer E, Jerman J. Transgender abortion patients and the provision of transgender-specific care at non-hospital facilities that provide abortions. Contracept X. 2020;2:100019.
pubmed: 32550534
pmcid: 7286144
Light A, Wang L-F, Zeymo A, Gomez-Lobo V. Family planning and contraception use in transgender men. Contraception. 2018;98:266–9.
pubmed: 29944875
Schneider F, Kliesch S, Schlatt S, Neuhaus N. Andrology of male-to-female transsexuals: influence of cross-sex hormone therapy on testicular function. Andrology. 2017;5:873–80.
pubmed: 28914501
Coleman E, Bockting W, Botzer M, Cohen-Kettenis P, De Cuypere G, Feldman J, et al. Standards of care for the health of transsexual transgender, and gender-non- conforming people, version 7. Int J Transgenderism. 2011;13:165–232.
T’Sjoen G, Arcelus J, De Vries ALC, Fisher AD, Nieder TO, Özer M, et al. European Society for Sexual Medicine Position Statement “Assessment and Hormonal Management in Adolescent and Adult Trans People, With Attention for Sexual Function and Satisfaction”. J Sex Med. 2020;17:570–84.
pubmed: 32111534
Gooren LJ. Management of female-to-male transgender persons: medical and surgical management, life expectancy. Curr Opin Endocrinol Diabetes Obes. 2014;21:233–8.
pubmed: 24755998
Irwig MS. Testosterone therapy for transgender men. Lancet Diabetes Endocrinol. 2017;5:301–11.
pubmed: 27084565
Meriggiola MC, Gava G. Endocrine care of transpeople part I. A review of cross-sex hormonal treatments, outcomes and adverse effects in transmen. Clin Endocrinol. 2015;83:597–606.
Pelusi C, Costantino A, Martelli V, Lambertini M, Bazzocchi A, Ponti F, et al. Effects of three different testosterone formulations in female-to-male transsexual persons. J Sex Med. 2014;11:3002–11.
pubmed: 25250780
Krempasky C, Harris M, Abern L, Grimstad F. Contraception across the transmasculine spectrum. Am J Obstet Gynecol. 2020;222:134–43.
pubmed: 31394072
Gomez A, Walters P, Dao LT. “Testosterone in a way is birth control”: contraceptive attitudes and experiences among transmasculine and genderqueer young adults. Contraception. 2016;94:422–3.
Light AD, Obedin-Maliver J, Sevelius JM, Kerns JL. Transgender men who experienced pregnancy after female-to-male gender transitioning. Obstet Gynecol. 2014;124:1120–7.
pubmed: 25415163
Schubert FD, Carey JM. Data unclear on pregnancy risk in transmasculine individuals on testosterone. Am J Obstet Gynecol. 2020;222:393–4.
pubmed: 31870734
Spinder T, Spijkstra JJ, van den Tweel JG, Burger CW, van Kessel H, Hompes PG, et al. The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects. J Clin Endocrinol Metab. 1989;69:151–7.
pubmed: 2471710
De Roo C, Lierman S, Tilleman K, Peynshaert K, Braeckmans K, Caanen M, et al. Ovarian tissue cryopreservation in female-to-male transgender people: insights into ovarian histology and physiology after prolonged androgen treatment. Reprod Biomed Online. 2017;34:557–66.
pubmed: 28372892
Berra M, Armillotta F, D’Emidio L, Costantino A, Martorana G, Pelusi G, et al. Testosterone decreases adiponectin levels in female to male transsexuals. Asian J Androl. 2006;8:725–9.
pubmed: 16855767
Perrone AM, Cerpolini S, Maria Salfi NC, Ceccarelli C, Badiali de Giorgi L, Formelli G, et al. Effect of long-term testosterone administration on the endometrium of female-to-male (FtM) transsexuals. J Sex Med. 2009;6:3193–200.
pubmed: 19570144
Deutsch MB, Bhakri V, Kubicek K. Effects of cross-sex hormone treatment on transgender women and men. Obstet Gynecol. 2015;125:605–10.
pubmed: 25730222
pmcid: 4442681
Caanen MR, Soleman RS, Kuijper EA, Kreukels BPC, De Roo C, Tilleman K, et al. Antimullerian hormone levels decrease in female-to-male transsexuals using testosterone as cross-sex therapy. Fertil Steril. 2015;103:1340–5.
pubmed: 25772768
Taub RL, Ellis SA, Neal-Perry G, Magaret AS, Prager SW, Micks EA. The effect of testosterone on ovulatory function in transmasculine individuals. Am J Obstet Gynecol. 2020;S0002-9378:30134–4.
Futterweit W. Endocrine therapy of transsexualism and potential complications of long-term treatment. Arch Sex Behav. 1998;27:209–26.
pubmed: 9562902
Grimstad FW, Fowler KG, New EP, Ferrando CA, Pollard RR, Chapman G, et al. Uterine pathology in transmasculine persons on testosterone: a retrospective multicenter case series. Am J Obstet Gynecol. 2019;220:257.e1–257.e7.
Loverro G, Resta L, Dellino M, Di Naro E, Cascarano MA, Loverro M, et al. Uterine and ovarian changes during testosterone administration in young female-to-male transsexuals. Taiwan J Obstet Gynecol. 2016;55:686–91.
pubmed: 27751416
Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome: part 1. Endocr Pract. 2015;21:1291–300.
pubmed: 26509855
West S, Vähäsarja M, Bloigu A, Pouta A, Franks S, Hartikainen AL, et al. The impact of self-reported oligo-amenorrhea and hirsutism on fertility and lifetime reproductive success: results from the Northern Finland Birth Cohort 1966. Hum Reprod. 2014;29:628–33.
pubmed: 24324025
Casteràs A, De Silva P, Rumsby G, Conway GS. Reassessing fecundity in women with classical congenital adrenal hyperplasia (CAH): normal pregnancy rate but reduced fertility rate. Clin Endocrinol. 2009;70:833–7.
Schwartz AR, Russell K, Gray BA. Approaches to vaginal bleeding and contraceptive counseling in transgender and gender nonbinary patients. Obstet Gynecol. 2019;134:81–90.
pubmed: 31188325
Mehringer J, Dowshen NL. Sexual and reproductive health considerations among transgender and gender-expansive youth. Curr Probl Pediatr Adolesc Health Care. 2019;49:100684.
pubmed: 31735693
Abern L, Maguire K. Contraception knowledge in transgender individuals: are we doing enough? Obstet Gynecol. 2018;131:65S.
Stark B, Hughto JMW, Charlton BM, Deutsch MB, Potter J, Reisner SL. The contraceptive and reproductive history and planning goals of trans-masculine adults: a mixed-methods study. Contraception. 2019;100:468–73.
pubmed: 31400297
pmcid: 7357713
Cipres D, Seidman D, Cloniger C 3rd, Nova C, O’Shea A, Obedin-Maliver J. Contraceptive use and pregnancy intentions among transgender men presenting to a clinic for sex workers and their families in San Francisco. Contraception. 2017;95:186–9.
pubmed: 27621044
Trussell J, Aiken ARA, Micks E, Guthrie KA. Efficacy, safety, and personal considerations. In: Hatcher RA, Nelson AL, Trussell J, Cwiak C, Cason P, Policar MS, Edelman A, Aiken ARA, Marrazzo J, Kowal D, editors. Contraceptive technology. 21st ed. New York, NY: Ayer Company Publishers, Inc.; 2018.
Francis A, Jasani S, Bachmann G. Contraceptive challenges and the transgender individual. Women’s Midlife Health. 2018;4:12.
pubmed: 30766722
pmcid: 6297942
Curtis KM, Jatlaoui TC, Tepper NK, Zapata LB, Horton LG, Jamieson DJ, et al. U.S. Selected practice recommendations for contraceptive use, 2016. MMWR Morb Mortal Wkly Rep. 2016;1–66. Accessed 1 Feb 2021.
World Health Organization. Medical eligibility criteria for contraceptive use. Third edition, 2004. http://apps.who.int/iris/bitstream/10665/42907/1/9241562668.pdf . Accessed 28 Jun 2018.
Faculty of Sexual & Reproductive Healthcare (FSRH). UK Medical Eligibility Criteria for Contraceptive Use (UKMEC) 2016. 2016. http://www.fsrh.org/standards-and-guidance/ukmedical-eligibility-criteria-for-contraceptive-use/ .
Bates CK, Carroll N, Potter J. The challenging pelvic examination. J Gen Intern Med. 2011;26:651–7.
pubmed: 21225474
pmcid: 3101979
Ali M, Akin A, Bahamondes L, Brache V, Habib N, Landoulsi S, et al. WHO study group on subdermal contraceptive implants for women. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant. Hum Reprod. 2016;31:2491–8.
pubmed: 27671673
pmcid: 5088635
Wolters Kluwer Health, Inc. Etonogestrel implant. Lexi-drugs. Lexicomp. http://online.lexi.com . Accessed 2 May 2019.
Mansour D, Korver T, Marintcheva- Petrova M, Fraser IS. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care. 2008;13:13–28.
pubmed: 18330814
Funk S, Miller MM, Mishell DR, Archer DF, Poindexter A, Schmidt J, et al. Safety and efficacy of implanon, a single-rod implant- able contraceptive containing etonogestrel. Contraception. 2005;71:319–26.
pubmed: 15854630
Hodax JK, Wagner J, Sackett-Taylor AC, Rafferty J, Forcier M. Medical options for care of gender diverse and transgender youth. J Pediatr Adolesc Gynecol. 2020;33:3–9.
pubmed: 31154017
Wolters Kluwer Health, Inc. Medroxyprogesterone acetate. Lexi-drugs. Lexicomp. http://online.lexi.com . Accessed 2 May 2019.
Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial [published correction appears in Lancet. 2019 Jul 27;394(10195):302]. Lancet. 2019;394:303–13.
Baillargeon J, Urban RJ, Morgentaler A, Glueck CJ, Baillargeon G, Sharma G, et al. Risk of venous thromboembolism in men receiving testosterone therapy. Mayo Clin Proc. 2015;90:1038–45.
pubmed: 26205547
Snyder PJ, Ellenberg SS, Farrar JT. Effects of testosterone treatment in older men. N Engl J Med. 2016;374:611–24.
pubmed: 26886521
pmcid: 5209754
Shatzel JJ, Connelly KJ, DeLoughery TG. Thrombotic issues in transgender medicine: a review. Am J Hematol. 2017;92:204–8.
pubmed: 27779767
Boudreau D, Mukerjee R. Contraception care for transmasculine individuals on testosterone therapy. J Midwifery Women’s Health. 2019;64:395–402.
Fraser HM. GnRH analogues for contraception. Br Med Bull. 1993;49:62–72.
pubmed: 8324616
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 208 Summary: Benefits and Risks of Sterilization. Obstet Gynecol. 2019;133:592–4.
Chen D, Matson M, Macapagal K, Johnson EK, Rosoklija I, Finlayson C, et al. Attitudes toward fertility and reproductive health among transgender and gender-nonconforming adolescents. J Adolesc Health. 2018;63:62–8.
pubmed: 29503031
pmcid: 6067953
Jones K, Wood M, Stephens L. Contraception choices for transgender males. J Fam Plan Reprod Health Care. 2017;43:239–40.
Lexicomp. Testosterone: drug information. Alphen aan den Rijn, The Netherlands: Wolters Kluwer; 2018. Accessed 10 Oct 2018.
Defreyne J, Van Schuylenbergh J, Motmans J, Tilleman KL, T’Sjoen GGR. Parental desire and fertility preservation in assigned female at birth transgender people living in Belgium. Fertil Steril. 2020;113:149–157.e2.
pubmed: 31727413
Meriggiola MC, Gava G. Endocrine care of transpeople part II. A review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen. Clin Endocrinol . 2015;83:607–15.
Asscheman H, T’Sjoen G, Lemaire A, Mas M, Meriggiola MC, Mueller A, et al. Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review. Andrologia. 2014;46:791–5.
pubmed: 23944849
Wierckx K, Van Caenegem E, Schreiner T, Haraldsen I, Fisher AD, Toye K, et al. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence [published correction appears in J Sex Med. 2016;13(4):732]. J Sex Med. 2014;11:1999–2011.
pubmed: 24828032
Mamoojee Y, Seal LJ, Quinton R. Transgender hormone therapy: understanding international variation in practice. Lancet Diabetes Endocrinol. 2017;5:243–6.
pubmed: 28340645
Liu PY, Swerdloff RS, Christenson PD, Handelsmann DJ, Wang C. Hormonal Male Contraception Summit Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet. 2006;367:1412–20.
pubmed: 16650651
Gava G, Meriggiola MC. Update on male hormonal contraception. Ther Adv Endocrinol Metab. 2019;10:2042018819834846.
pubmed: 30899448
pmcid: 6419257
Neblett MF 2nd, Hipp HS. Fertility considerations in transgender persons. Endocrinol Metab Clin N Am. 2019;48:391–402.
Sapino A, Pagani A, Godano A, Bussolati G. Effects of estrogens on the testis of transsexuals: a pathological and immunocytochemical study. Virchows Arch A Pathol Anat Histopathol. 1987;411:409–14.
pubmed: 3116755
Lübbert H, Leo-Rossberg I, Hammerstein J. Effects of ethinyl estradiol on semen quality and various hormonal parameters in a eugonadal male. Fertil Steril. 1992;58:603–8.
pubmed: 1387850
Schulze C. Response of the human testis to long-term estrogen treatment: morphology of Sertoli cells, Leydig cells and spermatogonial stem cells. Cell Tissue Res. 1988;251:31–43.
pubmed: 3342442
Rodriguez-Rigau LJ, Tcholakian RK, Smith KD, Steinberger E. In vitro steroid metabolic studies in human testes. II: metabolism of cholesterol, pregnenolone, progesterone, androstenedione and testosterone by testes of an estrogen-treated man. Steroids. 1977;30:729–39.
pubmed: 611638
Thiagaraj D, Gunasegaram R, Loganath A, Peh KL, Kottegoda SR, Ratnam SS. Histopathology of the testes from male transsexuals on oestrogen therapy. Ann Acad Med Singap. 1987;16:347–8.
pubmed: 3688813
Payer AF, Meyer WJ 3rd, Walker PA. The ultrastructural response of human Leydig cells to exogenous estrogens. Andrologia. 1979;11:423–36.
pubmed: 532984
Schneider F, Neuhaus N, Wistuba J, Zitzmann M, Hess J, Mahler D, et al. Testicular functions and clinical characterization of patients with gender dysphoria (GD) undergoing sex reassignment surgery (SRS). J Sex Med. 2015;12:2190–200.
pubmed: 26559385
Matoso A, Khandakar B, Yuan S, Wo T, Wang LJ, Lombardo KA, et al. Spectrum of findings in orchiectomy specimens of persons undergoing gender confirmation surgery. Hum Pathol. 2018;76:91–9.
pubmed: 29555572
Leavy M, Trottmann M, Liedl B, Reese S, Stief C, Freitag B, et al. Effects of elevated beta-estradiol levels on the functional morphology of the testis—new insights. Sci Rep. 2017;7:39931.
pubmed: 28045098
pmcid: 5206739
Jindarak S, Nilprapha K, Atikankul T, Angspatt A, Pungrasmi P, Iamphongsai S, et al. Spermatogenesis abnormalities following hormonal therapy in transwomen. Biomed Res Int. 2018;2018:7919481.
pubmed: 29808166
pmcid: 5902106
Fainberg J, Kashanian JA. Vasectomy. JAMA. 2018;319:2450.
pubmed: 29922830
Haley SG, Tordoff DM, Kantor AZ, Crouch JM, Ahrens KR. Sex education for transgender and non-binary youth: previous experiences and recommended content. J Sex Med. 2019;16:1834–48. https://doi.org/10.1016/j.jsxm.2019.08.009.
doi: 10.1016/j.jsxm.2019.08.009.
pubmed: 31585806
James SE, Herman JL, Rankin S, Keisling M, Mottet L, Anafi M. The Report of the 2015 U.S. Transgender Survey. Washington, DC: National Center for Transgender Equality. 2016.
Goldenberg T, Jadwin-Cakmak L, Harper GW. Intimate partner violence among transgender youth: associations with intra-personal and structural factors. Violence Gend. 2018;5:19–25.
pubmed: 29588911
pmcid: 5865252
Garofalo R, Deleon J, Osmer E, Doll M, Harper GW. Overlooked, misunderstood and at-risk: exploring the lives and HIV risk of ethnic minority male-to-female transgender youth. J Adolesc Health. 2006;38:230–6.
pubmed: 16488820
Bhasin S, Heber D, Steiner B, Peterson M, Blaisch B, Campfield LA, et al. Hormonal effects of GnRH agonist in the human male: II. Testosterone enhances gonadotrophin suppression induced by GnRH agonist. Clin Endocrinol (Oxf). 1984;20:119–28.
pubmed: 6232019
Wingo E, Ingraham N, Roberts SCM. Reproductive health care priorities and barriers to effective care for LGBTQ people assigned female at birth: a qualitative study. Women’s Health Issues. 2018;28:350–7.
pubmed: 29661698
Trussell J. Contraceptive failure in the United States. Contraception. 2011;83:397–404.
pubmed: 21477680
pmcid: 3638209
Coukell AJ, Balfour JA. Levonorgestrel subdermal implants. A review of contraceptive efficacy and acceptability. Drugs. 1998;55:861–87.
pubmed: 9617600
Meckstroth KR, Darney PD. Implant contraception. Semin Reprod Med. 2001;19:339–54.
pubmed: 11727176
Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril. 2012;97:616e22.
Fuchs A, Matonóg A, Sieradzka P, Pilarska J, Hauzer A, Czech I, et al. Anti-androgenic therapy in young patients and its impact on intensity of hirsutism, acne, menstrual pain intensity and sexuality - a preliminary study. Ginekol Pol. 2019;90:520–6.
pubmed: 31588549
Jeng CJ, Chuang L, Shen J. A comparison of progestogens or oral contraceptives and gonadotropin-releasing hormone agonists for the treatment of endometriosis: a systematic review. Expert Opin Pharmacother. 2014;15:767–73.
pubmed: 24588662
Stone SC. Desogestrel. Clin Obstet Gynecol. 1995;38:821–8.
pubmed: 8616978
Dianat S, Fox E, Ahrens KA, Upadhyay UD, Zlidar VM, Gallo MF, et al. Side effects and health benefits of depot medroxyprogesterone acetate: a systematic review. Obstet Gynecol. 2019;133:332–41.
pubmed: 30633132
Zigler RE, McNicholas C. Unscheduled vaginal bleeding with progestin-only contraceptive use. Am J Obstet Gynecol. 2017;216:443–50.
pubmed: 27988268
Chi IC. An evaluation of the levonorgestrel-releasing IUD: its advantages and disadvantages when compared to the copper-releasing IUDs. Contraception. 1991;44:573–88.
pubmed: 1773615
Lethaby A, Wise MR, Weterings MA, Rodriguez MB, Brown J. Combined hormonal contraceptives for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019;2:CD000154.
pubmed: 30742315
Mansour D, Gemzell-Danielsson K, Inki P, Jensen JT. Fertility after discontinuation of contraception: a comprehensive review of the literature. Contraception. 2011;84:465–77.
pubmed: 22018120